Quantitative profiling of single formalin fixed tumour sections: Proteomics for translational research

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hughes, Christopher S ^a   Mcconechy, Melissa K ^b   Cochrane, Dawn R ^a   Nazeran, Tayyebeh ^c   Karnezis, Anthony N ^c   Huntsman, David G ^a,c   Morin, Gregg B ^a,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; TUMOR PROTEIN;

ADENOCARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MASS SPECTROMETRY; METABOLISM; OVARY TUMOR; PATHOLOGY; PEPTIDE MAPPING; PROCEDURES; PROTEOGENOMICS; PROTEOMICS; TISSUE FIXATION; TRANSLATIONAL RESEARCH;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; FEMALE; FORMALDEHYDE; GENE EXPRESSION PROFILING; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEPTIDE MAPPING; PROTEOGENOMICS; PROTEOMICS; TISSUE FIXATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84990957266     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34949     Document Type: Article

References (67)

1. Sallam R. M. Proteomics in Cancer Biomarkers Discovery: Challenges, and Applications. Dis. Markers 2015, 12 (2015
2. Gustafsson O. J. R, Arentz G, & Hoffmann P. Proteomic developments in the analysis of formalin-fixed tissue. Biochim. Biophys. Acta - Proteins Proteomics 1854, 559-580 (2015
3. Zhang B, et al. Proteogenomic characterization of human colon, and rectal cancer. Nature 513, 382-387 (2014
4. Mertins P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 1-19, doi: 10.1038/nature18003 (2016
5. Zhang H, et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell, doi: 10.1016/j. cell.2016.05.069 (2016
6. Tyanova S, et al. Proteomic maps of breast cancer subtypes. Nat. Commun. 7, 10259 (2016
7. Pozniak Y, et al. System-wide Clinical Proteomics of Breast Cancer Reveals Global Remodeling of Tissue Homeostasis. Cell Syst. 2, 172-184 (2016
8. Wisniewski J. R, Ostasiewicz P, & Mann M. High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J. Proteome Res. 10, 3040-3049 (2011
9. Wiśniewski J. R, et al. Extensive quantitative remodeling of the proteome between normal colon tissue, and adenocarcinoma. Mol. Syst. Biol. 8, 611 (2012
10. Wiśniewski J. R, et al. Absolute Proteome Analysis of Colorectal Mucosa, Adenoma, and Cancer Reveals Drastic Changes in Fatty Acid Metabolism, and Plasma Membrane Transporters. J. Proteome Res. 14, 4005-4018 (2015
11. Quesada-Calvo F, et al. Comparison of two FFPE preparation methods using label-free shotgun proteomics: Application to tissues of diverticulitis patients. J. Proteomics 112C, 250-261 (2014
12. Wisniewski J. R, Zielinska D. F, & Mann M. Comparison of ultrafiltration units for proteomic, and N-glycoproteomic analysis by the filter-Aided sample preparation method. Anal. Biochem. 410, 307-309 (2011
13. Shih I.-M, & Kurman R. J. Ovarian Tumorigenesis. Am. J. Pathol. 164, 1511-1518 (2004
14. Bell D. a. Origins, and molecular pathology of ovarian cancer. Mod. Pathol. 18 Suppl 2, S19-S32 (2005
15. Köbel M, et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 5, 1749-1760 (2008
16. Köbel M, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am. J. Surg. Pathol. 34, 984-993 (2010
17. Kurman R. J, & Shih I. M. Molecular pathogenesis, and extraovarian origin of epithelial ovarian cancer - Shifting the paradigm. Human Pathology 42, 918-931 (2011
18. Konstantinopoulos P. a, Spentzos D, & Cannistra S. a. Gene-expression profiling in epithelial ovarian cancer. Nat. Clin. Pract. Oncol. 5, 577-587 (2008
19. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011
20. Elzek M. A, & Rodland K. D. Proteomics of ovarian cancer: functional insights, and clinical applications. Cancer Metastasis Rev. 34, 83-96 (2015
21. Albert F. W, & Kruglyak L. The role of regulatory variation in complex traits, and disease. Nat. Rev. Genet. 16, 197-212 (2015
22. Hughes C. S, et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol. Syst. Biol. 10, 1-14 (2014
23. Thompson A, et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/.MS. Anal. Chem. 75, 1895-1904 (2003
24. Shi S.-R, Liu C, Balgley B. M, Lee C, & Taylor C. R. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J. Histochem. Cytochem. 54, 739-743 (2006
25. Uhlen M, et al. Tissue-based map of the human proteome. Science (80-. ). 347, 1260419-1260419 (2015
26. Köbel M, et al A limited panel of immunomarkers can reliably distinguish between clear cell, and high-grade serous carcinoma of the ovary. Am. J. Surg. Pathol. 33, 14-21 (2009
27. Zorn K. K. Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian, and Endometrial Cancer. Clin. Cancer Res. 11, 6422-6430 (2005
28. Spentzos D. Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer. J. Clin. Oncol. 22, 4700-4710 (2004
29. Schwartz D. R, et al. Gene Expression in Ovarian Cancer Reflects Both Morphology, and Biological Behavior. Distinguishing Clear Cell from Other Poor-Prognosis Ovarian Carcinomas Gene Expression in Ovarian Cancer Reflects Both Morphology, and Biological. 4722-4729 (2002
30. Uehara Y, et al. Integrated Copy Number, and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations, and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas. PLoS One 10 (2015
31. Tripathi S, et al. Meta-, and Orthogonal Integration of Influenza ?OMICs? Data Defines a Role for UBR4 in Virus Budding. Cell Host Microbe 18, 723-735 (2015
32. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005
33. Yamaguchi K, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology, and the carcinogenic processes. Oncogene 29, 1741-1752 (2010
34. Pontén F, et al A global view of protein expression in human cells, tissues, and organs. Mol. Syst. Biol. 5, 337 (2009
35. de Sousa Abreu R, Penalva L. O, Marcotte E. M, & Vogel C. Global signatures of protein, and mRNA expression levels. Mol. Biosyst. 5, 1512-1526 (2009
36. Maier T, Güell M, & Serrano L. Correlation of mRNA, and protein in complex biological samples. FEBS Lett. 583, 3966-3973 (2009
37. Vogel C, & Marcotte E. M. Insights into the regulation of protein abundance from proteomic, and transcriptomic analyses. Nat. Rev. Genet. 13, 227-232 (2012
38. Vergote I. B, Marth C, & Coleman R. L. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 34, 41-52 (2015
39. Köbel M, et al. Evidence for a time-dependent association between FOLR1 expression, and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br. J. Cancer 111, 2297-2307 (2014
40. Dhanoa B. S, Cogliati T, Satish A. G, Bruford E. A, & Friedman J. S. Update on the Kelch-like (KLHL) gene family. Hum. Genomics 7, 13 (2013
41. Márquez A, et al. Effect of BSN-MST1 locus on inflammatory bowel disease, and multiple sclerosis susceptibility. Genes Immun. 10, 631-635 (2009
42. Sasaki A, et al. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis, and epithelial ovarian cancer. Int. J. Cancer 136, 1985-1990 (2015
43. O?Shannessy D. J, et al. Serum folate receptor alpha, mesothelin, and megakaryocyte potentiating factor in ovarian cancer: association to disease stage, and grade, and comparison to CA125, and HE4. J. Ovarian Res. 6, 29 (2013
44. Tabibzadeh S, & Hemmati-Brivanlou A. Lefty at the crossroads of ?stemness?, and differentiative events. Stem Cells 24, 1998-2006 (2006
45. Postovit L.-M, Seftor E. a, Seftor R. E. B, & Hendrix M. J. C. Targeting Nodal in malignant melanoma cells. Expert Opin. Ther. Targets 11, 497-505 (2007
46. Quail D. F, et al. Embryonic protein nodal promotes breast cancer vascularization. Cancer Res. 72, 3851-3863 (2012
47. Quail D. F, et al. Embryonic Morphogen Nodal Promotes Breast Cancer Growth, and Progression. PLoS One 7 (2012
48. Quail D. F, Zhang G, Findlay S. D, Hess D. a, & Postovit L.-M. Nodal promotes invasive phenotypes via a mitogen-Activated protein kinase-dependent pathway. Oncogene 33, 461-473 (2014
49. Hughes C, et al. Mass spectrometry-based proteomic analysis of the matrix microenvironment in pluripotent stem cell culture. Mol. Cell. Proteomics 11, 1924-1936 (2012
50. Postovit L.-M, et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc. Natl. Acad. Sci. USA 105, 4329-4334 (2008
51. Wang R. Two?s company, three?s a crowd: can H2S be the third endogenous gaseous transmitter?. FASEB J. 16, 1792-1798 (2002
52. Bhattacharyya S, et al. Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression, and Drug Resistance. PLoS One 8 (2013
53. Mandai M, et al. Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect, and ROS reduction. Oncotarget 6, 30704-14 (2015
54. Tsuchiya A, et al. Expression Profiling in Ovarian Clear Cell Carcinoma. Am. J. Pathol. 163, 2503-2512 (2003
55. Yamamoto S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1β in ovarian, and endometrial clear-cell adenocarcinomas, and nonneoplastic endometrium. Hum. Pathol. 38, 1074-1080 (2007
56. Käll L, Canterbury J. D, Weston J, Noble W. S, & MacCoss M. J. Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat. Methods 4, 923-925 (2007
57. Spivak M, et al. Improvements to the Percolator Algorithm for Peptide Identi cation from Shotgun Proteomics Data Sets. J. Proteome Res. 8, 3737-3745 (2009
58. Karp N. a, et al. Addressing accuracy, and precision issues in iTRAQ quantitation. Mol. Cell. Proteomics 9, 1885-1897 (2010
59. Suomi T, Corthals G. L, Nevalainen O. S, & Elo L. L. Using Peptide-Level Proteomics Data for Detecting Differentially Expressed Proteins. J. Proteome Res. 14, 4564-4570 (2015
60. Huber W, von Heydebreck A, Sültmann H, Poustka A, & Vingron M. Variance stabilization applied to microarray data calibration, and to the quantification of differential expression. Bioinformatics 18 Suppl 1, S96-S104 (2002
61. Smyth G. K. Linear models, and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3 (2004
62. Wu Z, Irizarry R. a, Gentleman R, Martinez-Murillo F, & Spencer F A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. J. Am. Stat. Assoc. 99, 909-917 (2004
63. Cerami E, et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012
64. Goeman J. J, & Bühlmann P. Analyzing gene expression data in terms of gene sets: Methodological issues. Bioinformatics 23, 980-987 (2007
65. Reimand J, Kull M, Peterson H, Hansen J, & Vilo J. g: Profiler-A web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 35, W193-W200 (2007
66. Vizcaíno J, Deutsch E, & Wang R. ProteomeXchange provides globally coordinated proteomics data submission, and dissemination. Nat. 32, 223-226 (2014
67. Vizcaíno J. A, et al. 2016 update of the PRIDE database, and its related tools. Nucleic Acids Res. 44, D447-D456 (2016